📋 Browse Articles

To investigate longitudinal changes in neuroimmune biomarkers during acute exacerbations of chronic obstructive pulmonary disease (AECOPD), their modulation by standard therapy, and prognostic implications for 90-day outcomes. In a prospective cohort, 266 hospitalized AECOPD patients were stratified into worsened ( Compared with controls, AECOPD patients exhibited higher IL-6, TNF-α, PD-1, and MMP-9, alongside reduced BDNF and IL-10. Stable patients demonstrated partial biomarker normalization, whereas worsened patients retained a pro-inflammatory profile. Corticosteroids and antibiotics attenuated cytokine elevations, and oxygen therapy facilitated BDNF recovery. Low BDNF and high MMP-9 predicted spirometric decline, while elevated PD-1 and MMP-9 were associated with increased 90-day readmission risk. A dual-axis model incorporating neurotrophic and immune exhaustion markers outperformed GOLD classification for risk prediction. Neuroimmune biomarkers capture recovery heterogeneity in AECOPD. The proposed dual-axis model improves prognostic accuracy and may inform personalized management strategies. Show less

Shatavarin IV, a steroidal saponin in Cells were treated with shatavarin IV (10 ng/ml) or proprietary ethanolic extract of shatavari root extract (SheVari4 In LPS-induced cells treated with shatavarin IV, IL6 and TNFα levels were reduced by 46% and 50%, respectively, and those of IL-10 and TGF-β were upregulated by 2.74 and 4.4 times with significant reductions in ROS and NO levels. Similar results were observed in presence of SheVari4 The results suggested that the primary bioactive component of Show less